Diabetic cardiomyopathy (Q42318): Difference between revisions
From determinar.ia.br - Determine suas informações
Created a new Item |
Changed label, description and/or aliases in pt-br, en |
||
| description / pt-br | description / pt-br | ||
Cardiomiopatia diabética é a presença de disfunção miocárdica na ausência de doença arterial coronariana clínica evidente, doença valvar e outros fatores de risco cardiovascular convencionais, como hipertensão e dislipidemia. Caracteriza-se inicialmente por fibrose miocárdica, remodelamento disfuncional e disfunção diastólica, evoluindo para disfunção sistólica e insuficiência cardíaca. _x000D_ _x000D_ Informações adicionais. O desenvolvimento e a progressão de cardiomiopatia diabética têm sido associados ao comprometimento da sinalização metabólica da insulina no coração, aumento do estresse oxidativo, redução da biodisponibilidade do óxido nítrico, rigidez da matriz extracelular e dos cardiomiócitos a base de colágeno, comprometimento do manuseio do cálcio por mitocôndrias e cardiomiócitos, inflamação, ativação do sistema renina-angiotensina-aldosterona, neuropatia autonômica cardíaca, estresse do retículo endoplasmático, disfunção microvascular e uma miríade de anormalidades metabólicas cardíacas. | |||
| description / en | description / en | ||
Diabetic cardiomyopathy is the presence of myocardial dysfunction in the absence of overt clinical coronary artery disease, valvar disease, and other conventional cardiovascular risk factors, such as hypertension and dyslipidemia. It is initially characterised by myocardial fibrosis, dysfunctional remodeling, and diastolic dysfunction, progressing to systolic dysfunction and heart failure. Additional information. The development and progression of diabetic cardiomyopathy has been linked to impaired cardiac insulin metabolic signaling, increases in oxidative stress, reduced nitric oxide bioavailability, collagen-based cardiomyocyte and extracellular matrix stiffness, impaired mitochondrial and cardiomyocyte calcium handling, inflammation, renin–angiotensin–aldosterone system activation, cardiac autonomic neuropathy, endoplasmic reticulum stress, microvascular dysfunction, and a myriad of cardiac metabolic abnormalities. | |||
Revision as of 08:46, 13 August 2026
Diabetic cardiomyopathy is the presence of myocardial dysfunction in the absence of overt clinical coronary artery disease, valvar disease, and other conventional cardiovascular risk factors, such as hypertension and dyslipidemia. It is initially characterised by myocardial fibrosis, dysfunctional remodeling, and diastolic dysfunction, progressing to systolic dysfunction and heart failure. Additional information. The development and progression of diabetic cardiomyopathy has been linked to impaired cardiac insulin metabolic signaling, increases in oxidative stress, reduced nitric oxide bioavailability, collagen-based cardiomyocyte and extracellular matrix stiffness, impaired mitochondrial and cardiomyocyte calcium handling, inflammation, renin–angiotensin–aldosterone system activation, cardiac autonomic neuropathy, endoplasmic reticulum stress, microvascular dysfunction, and a myriad of cardiac metabolic abnormalities.
| Language | Label | Description | Also known as |
|---|---|---|---|
| default for all languages | BC43.7 |
||
| English | Diabetic cardiomyopathy |
Diabetic cardiomyopathy is the presence of myocardial dysfunction in the absence of overt clinical coronary artery disease, valvar disease, and other conventional cardiovascular risk factors, such as hypertension and dyslipidemia. It is initially characterised by myocardial fibrosis, dysfunctional remodeling, and diastolic dysfunction, progressing to systolic dysfunction and heart failure. Additional information. The development and progression of diabetic cardiomyopathy has been linked to impaired cardiac insulin metabolic signaling, increases in oxidative stress, reduced nitric oxide bioavailability, collagen-based cardiomyocyte and extracellular matrix stiffness, impaired mitochondrial and cardiomyocyte calcium handling, inflammation, renin–angiotensin–aldosterone system activation, cardiac autonomic neuropathy, endoplasmic reticulum stress, microvascular dysfunction, and a myriad of cardiac metabolic abnormalities. |
